進行性運動失調症と衰弱障害治療の世界市場

Report Overview

Report Highlights

The global progressive ataxia and weakness disorders market reached $32.0 billion in 2022, should reach $35.1 billion by 2023 and $57.2 billion by 2028 with a compound annual growth rate (CAGR) of 10.2% during the forecast period of 2023-2028.

Report Includes

• 34 data tables and 34 additional tables
• A comprehensive overview of the current and future global markets for the treatments of progressive ataxia and weakness disorders
• Analyses of the global market trends, with historical market revenue data (sales figures) for 2022, estimates for 2023, forecasts for 2024 and 2026, and projections of compound annual growth rates (CAGRs) through 2028
• In-depth information (facts and figures) concerning the major factors influencing the progress of this market (benefits, and industry-specific challenges) with respect to specific growth trends, upcoming technologies, future prospects, and contributions to the overall market
• Estimation of the actual market size and revenue forecast for global progressive ataxia and weakness disorders treatments market in USD million values, and corresponding market share analysis based on product, technology, disease type, application, distribution channel, and region
• Discussion of the applications for neurodegenerative disorder treatment and therapy technologies, with emphasis on small-molecule and monoclonal antibodies technology
• Identification of critical medical and geographical challenges as well as economic and demographic factors affecting the market growth
• Review of key patent grants and recent patent applications on neurodegenerative (i.e., progressive ataxia and weakness) disorders in the pharmaceutical and biotechnology markets, along with emerging technologies and new developments
• Coverage of recent merger and acquisition (M&A) activities, venture fundings, and other impactful growth strategies in the global market neurodegenerative (i.e., progressive ataxia and weakness) disorders
• Identification of the key players operating in the market, and analysis of their competitive landscape based on recent developments, segmental revenues, and operational integration
• Company profiles of major players within the industry, including Abbott Laboratories, Glenmark Life Sciences, Novartis AG, Pfizer Inc., Roche Holding Ltd., and Sanofi

Report Scope

The scope of this study encompasses the neurodegenerative (i.e., progressive ataxia and weakness) disorders in the pharmaceutical and biotechnology markets. BCC analyzes each market and its applications, the technologies involved, market projections and market shares. Technological issues include the latest trends and developments. The emerging market for enzyme inhibitors includes India, China, Japan, Canada and Australia. The report informs all market players, potential entrants, government agencies and other interested parties. As the report covers geographic regions in detail, companies interested in expanding geographic reach will also find this helpful.

This report also covers merger and acquisition (M&A) strategies and collaborations, as well as the strengths and weaknesses of each strategy type.

Report Synopsis

Frequently Asked Questions (FAQs)

What is the projected market size and growth rate of Treatments for Syndromes of Progressive Ataxia and Weakness Disorders- Global Market?

The progressive ataxia and weakness disorders drug market is projected to grow from $32.0 billion in 2022 to $57.2 billion in 2028, at a compound annual growth rate (CAGR) of 10.2 % during the forecast period.

What are the key factors driving the growth of Treatments for Syndromes of Progressive Ataxia and Weakness Disorders- Global Market?

The key factors driving the growth of treatments for syndromes of progressive ataxia and weakness disorders- Global Market include:

• Increasing Prevalence of Neurological Disorders including Progressive Ataxia and Weakness Disorders and Awareness
• Technological advancements and product launch
• Increasing Expenditures for Health Care and investments for treatment for syndrome of Progressive Ataxia and Weakness Disorders
• Rise in alcohol and drug usage

What segments are covered in the Global Market of Treatments for Syndromes of Progressive Ataxia and Weakness Disorders?

In this report, the market is segmented based on type, technology, diseases, region and distributive channel. Based on the type, the market is segmented into progressive ataxia and progressive weakness disorders. Based on the technology, the market is segmented as small molecule, monoclonal antibody and others. Based on diseases, progressive ataxia is segmented as Friedreich ataxia, Machado Joseph disease/SCA3 and Gertsmann Straussler Scheinker diseases and progressive weakness disorders as multiple sclerosis, hereditary neuropathies, amyotrophic lateral sclerosis, progressive bulbar palsy and hereditary spastic paraplegia. Based on distributive channel, the market is segmented into retail pharmacy, hospital pharmacy and online pharmacy.

By Type, which segment will dominate the market by the end of 2028?

Progressive weakness disorders will dominate the market by the end of 2028.

Which region has the highest market share in the Global Market of Treatments for Syndromes of Progressive Ataxia and Weakness Disorders?

North America holds the highest share in the market.

Who are the key companies/players in the Global Market of Treatments for Syndromes of Progressive Ataxia and Weakness Disorders?

The major players in the market are Novartis AG, Pfizer Inc., Sanofi, Roche Holding Ltd. And Teva Pharmaceuticals.

Table of Contents

Chapter 1 Introduction
Overview
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
What’s New in This Update?
Methodology
Information Sources
Geographic Breakdown
Chapter 2 Summary and Highlights
Market Overview
Chapter 3 Market Overview
Introduction
Definitions
Neurons
Central Nervous System
Brain
Spinal Cord
Neurotransmitters
Classification
Progressive Ataxia and Weakness Disorders
Friedreich’s Ataxia
Gertsmann-Straussler-Scheinker Disease
Machado-Joseph Disease/SCA3
Amyotrophic Lateral Sclerosis
Hereditary Spastic Paraplegia
Hereditary Neuropathies
Multiple Sclerosis
Diagnostic Tests for Progressive Ataxia and Weakness Disorders
Diagnostic Tests for Multiple Sclerosis
Diagnostic Tests for Amyotrophic Lateral Sclerosis
Diagnostic Tests for Friedreich’s Ataxia
Diagnostic Tests for Machado-Joseph Disease
Diagnostic Tests for Hereditary Spastic Paraplegia
Diagnostic Tests for Hereditary Neuropathies
Chapter 4 Market Dynamics
Introduction
Market Drivers
Progressive Ataxia and Weakness: Increasing Prevalence and Awareness
Technological Advancements and Product Launch
Increasing Expenditures for Health Care
Rise in Alcohol and Drug Use
Market Barriers
Barriers to R&D for Progressive Ataxia
Diagnostic Challenges
Opportunities
Advancements in Research and Technology
Impact of COVID-19, Global Market for Treatment for Syndromes of Progressive Ataxia and Weakness Disorders
Chapter 5 Market Breakdown by Type and Technology
Introduction
Market by Type
Market Overview
Market Revenue
Market by Technology
Market Overview
Market Revenue
Small Molecule
Market Overview
Market Revenue
Monoclonal Antibody
Market Overview
Market Revenue
Others
Biomarkers
Gene Therapy
Stem Cell
Market Overview
Market Revenue
Chapter 6 Market Breakdown by Disease
Overview
Market Revenue
Market by Progressive Ataxia Diseases Type
Friedreich’s Ataxia
Market Revenue
Machado-Joseph disease (MJD)/SCA3
Market Revenue
Gertsmann-Straussler-Scheinker Disease
Market Revenue
Market by Disease Type
Amyotrophic Lateral Sclerosis
Progressive Bulbar Palsy
Hereditary Spastic Paraplegia
Hereditary Neuropathies (HNs)
Multiple Sclerosis (MS)
Chapter 7 Market Breakdown by Region
Introduction
North America
The U.S.
Canada
Europe
The UK
Germany
France
Spain
Italy
Russia
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
Rest of Asia-Pacific
Rest of the World
Market Size and Forecast
Chapter 8 Market Breakdown by Distribution Channel
Introduction
Retail Pharmacy
Hospital Pharmacy
Online Pharmacy
Chapter 9 Emerging Technologies and Developments
Introduction
Emerging Technology
Stem Cell Therapy
Gene Therapy
Biomarkers
Nasal Spray for MS
Disease-modifying Therapies
RNA-based Therapies
Conclusion
Chapter 10 ESG Development
Introduction
ESG Investments by Key Players
Consumer Attitudes Towards ESG
Conclusion
Chapter 11 Patent Analysis
Patent Analysis by Year
Chapter 12 M&A and Venture Funding Outlook and Competitive Landscape
Introduction
Mergers, Acquisitions and Collaborations
Strategic Initiatives
Market Shares of Manufacturers of Progressive Ataxia and Weakness Disorders Drugs
Chapter 13 Company Profiles
ABBOTT LABORATORIES
ACORDA THERAPEUTICS INC.
AMERICAN REGENT INC.
APOTEX INC.
APOTHECA INC.
ASTELLAS PHARMA INC.
ASTRAZENECA GMBH
BAXTER INTERNATIONAL INC.
BRISTOL-MYERS SQUIBB
EISAI CO. LTD.
ELI LILLY AND COMPANY
GILEAD SCIENCES INC.
GLAXOSMITHKLINE PLC
GLENMARK LIFE SCIENCES
JOHNSON & JOHNSON
MERCK KGAA
NOVARTIS AG
PFIZER INC.
ROCHE HOLDING LTD.
SANOFI
TAKEDA PHARMACEUTICAL CO. LTD.
TEVA PHARMACEUTICAL INDUSTRIES LTD.
Chapter 14 Appendix: Abbreviations

List of Tables

Summary Table A : Global Market for Treatments for Syndromes of Progressive Ataxia and Weakness Disorder Drugs, Through 2028
Summary Table B : Global Market for Progressive Ataxia and Weakness Disorders, Through 2028
Table 1 : Classification, by Primary Dysfunction
Table 2 : Drugs Approved in Europe for Multiple Sclerosis, 2011-2022
Table 3 : Global Market for Drug Products for the Treatment of Neurodegenerative Dysfunctions, Through 2028
Table 4 : Global Market for Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Technology, Through 2028
Table 5 : Global Market for Small Molecule Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Region, Through 2028
Table 6 : Global Market for Monoclonal Antibody Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Region, Through 2028
Table 7 : Global Market for Other Technology Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Region, Through 2028
Table 8 : Global Market for Drug Products for the Treatment of Progressive Ataxia, by Disease Type, Through 2028
Table 9 : Global Market for Friedreich’s Ataxia Drugs, by Region, Through 2028
Table 10 : Global Market for Machado-Joseph Disease (MJD) Drugs, by Region, Through 2028
Table 11 : Global Market for Gerstmann-Straussler-Scheinker (GSS) Drugs, by Region, Through 2028
Table 12 : Latest FDA Approvals for Amyotrophic Lateral Sclerosis
Table 13 : Drugs in Clinical Trials for ALS, 2022
Table 14 : Global Market for Amyotrophic Lateral Sclerosis Drugs, by Region, Through 2028
Table 15 : Global Market for Progressive Bulbar Palsy (PBP) Drugs, by Region, Through 2028
Table 16 : Global Market for Hereditary Spastic Paraplegia (HSP) Drugs, by Region, Through 2028
Table 17 : Global Market for Hereditary Neuropathies Drugs, by Region, Through 2028
Table 18 : Latest FDA Approvals for Multiple Sclerosis
Table 19 : Global Market for Multiple Sclerosis (MS) Drugs, by Region, Through 2028
Table 20 : Global Market for Progressive Ataxia and Weakness Disorders Drugs, by Region, Through 2028
Table 21 : North American Market for Progressive Ataxia and Weakness Disorders Drugs, by Country, Through 2028
Table 22 : European Market for Progressive Ataxia and Weakness Disorders Drugs, by Country, Through 2028
Table 23 : Asia-Pacific Market for Progressive Ataxia and Weakness Disorders Drugs, by Country, Through 2028
Table 24 : Global Market for Progressive Ataxia and Weakness Disorders Drugs, by Distributive Channel, Through 2028
Table 25 : Global Market for Progressive Ataxia and Weakness Disorders Drugs in Retail Pharmacy, by Region, Through 2028
Table 26 : Global Market for Progressive Ataxia and Weakness Disorders Drugs in Hospital Pharmacy, by Region, Through 2028
Table 27 : Global Market for Progressive Ataxia and Weakness Disorders Drugs in Online Pharmacy, by Region, Through 2028
Table 28 : ESG Ranking of Major Players,2022
Table 29 : ESG Investments, by Key Players, 2022
Table 30 : ESG Trends, Major Players, 2021
Table 31 : ESG Rankings for Major Companies, 2023
Table 32 : CDP Scope Card for Major Players, 2022
Table 33 : Patent Analysis, by Year, Jan. 2020 to March 2023
Table 34 : Major Companies Patents: 2022 to March 2023
Table 35 : M&A: Pharmaceutical Companies
Table 36 : Abbott Laboratories: Annual Revenue, 2022
Table 37 : Abbott Laboratories: News
Table 38 : Abbott Laboratories.: Product Portfolio
Table 39 : Acorda Therapeutics Inc.: News
Table 40 : Acorda Therapeutics Inc.: Product Portfolio
Table 41 : Eli Lily and Company: Annual Revenue, 2022
Table 42 : Eli Lily and Company: News
Table 43 : Eli Lily and Company: Product Portfolio
Table 44 : GlaxoSmithKline PLC: Annual Revenue, 2022
Table 45 : GlaxoSmithKline PLC: News
Table 46 : GlaxoSmithKline PLC: Product Portfolio
Table 47 : Glenmark Life Sciences: Annual Revenue, 2022
Table 48 : Glenmark Life Sciences: Product Portfolio
Table 49 : Novartis AG: Annual Revenue, 2022
Table 50 : Novartis AG: News
Table 51 : Novartis AG: Product Portfolio
Table 52 : Pfizer Inc.: Annual Revenue, 2022
Table 53 : Pfizer Inc.: News
Table 54 : Pfizer Inc.: Product Portfolio
Table 55 : Roche Holding Ltd.: Annual Revenue, 2022
Table 56 : Roche Holding Ltd.: News
Table 57 : Roche Holding Ltd.: Product Portfolio
Table 58 : Sanofi: Annual Revenue, 2022
Table 59 : Sanofi: News
Table 60 : Sanofi: Product Portfolio
Table 61 : Takeda Pharmaceutical Co. Ltd.: Annual Revenue, 2022
Table 62 : Takeda Pharmaceutical Co. Ltd.: News
Table 63 : Takeda Pharmaceutical Co. Ltd.: Product Portfolio
Table 64 : Teva Pharmaceutical Industries LTD.: Annual Revenue, 2022
Table 65 : Teva Pharmaceutical Industries LTD.: Product Portfolio
Table 66 : Abbreviations

List of Figures

Summary Figure A : Global Market for Treatments for Syndromes of Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Summary Figure B : Global Market for Progressive Ataxia and Weakness Disorders, 2020-2028
Figure 1 : Share of Global Health Expenditure Database, 2022
Figure 2 : Global Market for Drug Products for the Treatment of Neurodegenerative Dysfunctions, 2020-2028
Figure 3 : Global Market Shares of Drug Products for the Treatment of Neurodegenerative Dysfunctions, 2022
Figure 4 : Global Market for Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Technology, 2020-2028
Figure 5 : Global Market Shares of Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Technology, 2022
Figure 6 : Global Market for Small Molecule Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Region, 2020-2028
Figure 7 : Global Market for Monoclonal Antibody Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Region, 2020-2028
Figure 8 : Global Market for Other Technology Drug Products for the Treatment of Progressive Ataxia and Weakness Disorders, by Region, 2020-2028
Figure 9 : Global Market for Drug Products for the Treatment of Progressive Ataxia, by Disease Type, 2020-2028
Figure 10 : Global Market Shares of Drug Products for the Treatment of Progressive Ataxia, by Disease Type, 2022
Figure 11 : Global Market for Friedreich’s Ataxia Drugs, by Region, 2020-2028
Figure 12 : Global Market for Machado-Joseph Disease (MJD) Drugs, by Region, 2020-2028
Figure 13 : Global Market for Gerstmann-Straussler-Scheinker (GSS) Drugs, by Region, 2020-2028
Figure 14 : Global Market for Amyotrophic Lateral Sclerosis Drugs, by Region, 2020-2028
Figure 15 : Global Market for Progressive Bulbar Palsy (PBP) Drugs, by Region, 2020-2028
Figure 16 : Global Market for Hereditary Spastic Paraplegia (HSP) Drugs, by Region, 2020-2028
Figure 17 : Global Market for Hereditary Neuropathies Drugs, by Region, 2020-2028
Figure 18 : Global Market for Multiple Sclerosis (MS) Drugs, by Region, 2020-2028
Figure 19 : Global Market for Progressive Ataxia and Weakness Disorders Drugs, by Region, 2020-2028
Figure 20 : Global Market Shares of Progressive Ataxia and Weakness Disorders Drugs, by Region, 2022
Figure 21 : North American Market for Progressive Ataxia and Weakness Disorders Drugs, by Country, 2020-2028
Figure 22 : U.S. Market for Progressive Ataxia and Weakness Disorders Drug, 2020-2028
Figure 23 : Canadian Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 24 : European Market for Progressive Ataxia and Weakness Disorders Drugs, by Country, 2020-2028
Figure 25 : UK Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 26 : German Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 27 : French Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 28 : Spanish Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 29 : Italian Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 30 : Russian Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 31 : Rest of European Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 32 : Asia-Pacific Market for Progressive Ataxia and Weakness Disorders Drugs, by Country, 2020-2028
Figure 33 : Japanese Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 34 : Chinese Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 35 : Indian Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 36 : Australian Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 37 : Rest of Asia-Pacific Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 38 : Rest of the World Market for Progressive Ataxia and Weakness Disorders Drugs, 2020-2028
Figure 39 : Global Market for Progressive Ataxia and Weakness Disorders Drugs, by Distributive Channel, 2020-2028
Figure 40 : Global Market for Progressive Ataxia and Weakness Disorders Drugs in Retail Pharmacy, by Region, 2020-2028
Figure 41 : Global Market for Progressive Ataxia and Weakness Disorders Drugs in Hospital Pharmacy, by Region, 2020-2028
Figure 42 : Global Market for Progressive Ataxia and Weakness Disorders Drugs in Online Pharmacy, by Region, 2020-2028
Figure 43 : Benefits of Stem Cell Therapy for the Treatment of Syndrome of Progressive Ataxia and Weakness Disorders
Figure 44 : Environmental, Social and Governance Factors in the Pharmaceutical Industry for Syndromes of Progressive Ataxia and Weakness Disorders Market
Figure 45 : How A Strong ESG Proposition Benefits Pharmaceutical Business
Figure 46 : Share of ESG-Geographical Adoption Level Across All Industries, 2022
Figure 47 : Shares of Patents Registered/Approved, by Country, Jan. 2020 to July 2023
Figure 48 : Global Progressive Ataxia and Weakness Disorders Drugs Market Shares, by Key Manufacturers, 2022
Figure 49 : Abbott Laboratories: Annual Revenue, 2021 and 2022
Figure 50 : Abbott Laboratories: Revenue Shares, by Business Unit, 2022
Figure 51 : Abbott Laboratories.: Revenue Shares, by Region/Country, 2022
Figure 52 : Eli Lily and Company: Annual Revenue, 2021 and 2022
Figure 53 : Eli Lily and Company: Revenue Shares, by Business Unit, 2022
Figure 54 : Eli Lily and Company: Revenue Shares, by Region/Country, 2022
Figure 55 : GlaxoSmithKline PLC: Annual Revenue, 2021 and 2022
Figure 56 : GlaxoSmithKline PLC: Revenue Shares, by Business Unit, 2022
Figure 57 : GlaxoSmithKline PLC: Revenue Shares, by Region/Country, 2022
Figure 58 : Glenmark Life Sciences: Annual Revenue, 2021 and 2022
Figure 59 : Glenmark Life Sciences: Revenue Shares, by Business Unit, 2022
Figure 60 : Novartis AG: Annual Revenue, 2021 and 2022
Figure 61 : Novartis AG: Revenue Shares, by Business Unit, 2022
Figure 62 : Novartis AG: Revenue Shares, by Region, 2022
Figure 63 : Pfizer Inc.: Annual Revenue, 2021 and 2022
Figure 64 : Pfizer Inc.: Revenue Shares, by Business Unit, 2022
Figure 65 : Pfizer Inc.: Revenue Shares, by Region/Country, 2022
Figure 66 : Roche Holding Ltd.: Annual Revenue, 2021 and 2022
Figure 67 : Roche Holding Ltd.: Revenue Shares, by Business Unit, 2022
Figure 68 : Roche Holding Ltd.: Revenue Shares, by Region, 2022
Figure 69 : Sanofi: Annual Revenue, 2021 and 2022
Figure 70 : Sanofi: Revenue Shares, by Business Unit, 2022
Figure 71 : Sanofi: Revenue Shares, by Region/Country, 2022
Figure 72 : Takeda Pharmaceutical Co. Ltd.: Annual Revenue, 2021 and 2022
Figure 73 : Takeda Pharmaceutical Co. Ltd.: Revenue Shares, by Business Unit, 2022
Figure 74 : Takeda Pharmaceutical Company Limited: Revenue Shares, by Region/Country, 2022
Figure 75 : Teva Pharmaceutical Industries LTD.: Annual Revenue, 2021 and 2022
Figure 76 : Teva Pharmaceutical Industries LTD.: Revenue Shares, by Business Unit, 2022
Figure 77 : Teva Pharmaceutical Industries LTD.: Revenue Shares, by Region, 2022